Redeye comments on Fluoguide’s Q4 2022 report as we enter a catalyst-rich 2023e for the company. Fluoguide recently announced a slight delay in phase IIb HGG top-line data, though we judge that. | March 1, 2023
Copenhagen, Denmark, 6 November 2022 - FluoGuide A/S is pleased to announce that FG001 lights up in 5 out of 7 patients in an interim evaluation in the ongoing phase IIa trial in non-small cell lung. | November 6, 2022